Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

14.3%

5 terminated/withdrawn out of 35 trials

Success Rate

77.3%

-9.2% vs industry average

Late-Stage Pipeline

14%

5 trials in Phase 3/4

Results Transparency

0 of 17 completed trials have results

Key Signals

11 recruiting

Enrollment Performance

Analytics

Phase 2

16(61.5%)

Phase 3

5(19.2%)

Phase 1

3(11.5%)

N/A

2(7.7%)

26Total

Phase 2(16)

Phase 3(5)

Phase 1(3)

N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (35)

Showing 20 of 35 trials

NCT04305548Phase 2Recruiting

Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma

Role: lead

NCT04890067Recruiting

Observational Study in Localized Osteosarcoma

Role: lead

NCT04383119Phase 2Recruiting

Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma

Role: lead

NCT07328425Phase 2Recruiting

Clinical Study in Patients With DSRCT

Role: lead

NCT07265661Not ApplicableNot Yet Recruiting

Surgical Timing After Preoperative Hypofractionated Radiotherapy for Localized Extremity and Trunk Soft Tissue Sarcoma

Role: lead

NCT04749446Recruiting

Study on Clinical Features and Outcomes of Breast Sarcoma

Role: lead

NCT02986516Not ApplicableRecruiting

Sacral Chordoma: Surgery Versus Definitive Radiation Therapy in Primary Localized Disease

Role: lead

NCT02829437Recruiting

Observational Study on Endometrial Stromal Tumors

Role: lead

NCT04845893Recruiting

Observational Study on Skeletal Ewing's Sarcoma

Role: lead

NCT06375941Recruiting

Prospective Observational Study of Localized Angiosarcoma of Any Site: ProStars

Role: lead

NCT01710176Phase 3Completed

Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy

Role: lead

NCT03099681Recruiting

An Observational Study on Epithelioid Sarcoma

Role: lead

NCT03023124Phase 2Completed

Study With Trabectedin Versus Adriamycin Plus Dacarbazine, in Patients With Advanced Solitary Fibrous Tumor

Role: lead

NCT03838744Phase 2Completed

Randomized Trial in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.

Role: lead

NCT03840772Phase 2Completed

Eribulin in Advanced Solitary Fibrous Tumor

Role: lead

NCT01459484Phase 2Completed

ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic Osteosarcoma

Role: lead

NCT04274023Phase 2Terminated

Study on TSR-042 in Advanced Clear Cell Sarcoma

Role: lead

NCT04599660Completed

Study in Low Risk Gastrointestinal Stromal Tumor (GISTs)

Role: lead

NCT00928525Phase 2Completed

Imatinib in Patients With Desmoid Tumor and Chondrosarcoma

Role: lead

NCT02275286Phase 1Recruiting

Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients

Role: collaborator